Purinoceptor-mediated Modulation by Endogenous and Exogenous Agonists of Stimulation-evoked [3H]noradrenaline Release on Rat Iris
Overview
Affiliations
To investigate whether endogenous purinoceptor agonists affect the sympathetic neurotransmission in the rat isolated iris, and to classify the purinoceptors modulating exocytotic [3H]-noradrenaline release, we have determined the effect of adenosine receptor antagonists on, and the relative potency of selected agonists in modulating, the field stimulation-evoked (3 Hz, 2 min) [3H]-noradrenaline overflow. In addition, the apparent affinity constants of 8-phenyltheophylline (8-PT) and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) in antagonizing the prejunctional effects of purinoceptor agonists were estimated. The relatively A1-selective DPCPX 10 and 100 nmol/l increased the evoked [3H]-noradrenaline overflow by about 25%-35% indicating a minor inhibition of evoked release by endogenous purinoceptor agonists probably via an A1 adenosine receptor. Whereas the A1/A2-antagonist 8-PT failed to increase the evoked [3H]-noradrenaline overflow in the absence of exogenous agonists (without or with dipyridamole 1 mumol/l present), the relatively A2-selective antagonist CP-66,713 (4-amino-8-chloro-1-phenyl(1,2,4)triazolo(4,3-a)quinoxaline) 100 nmol/l decreased it by 20%-30% in the absence and continuous presence of DPCPX. This may be compatible with a minor A2-mediated facilitation by an endogenous purinoceptor agonist. All exogenous agonists tested (except UTP 100 mumol/1) inhibited the evoked [3H]-noradrenaline overflow. The relative order of agonist potency (IC40, concentration in mumol/l for inhibition of evoked release by 40%) was CPA (N6-(cyclopentyl)adenosine, 0.004) greater than R-PIA (R(-)N6-(2-phenylisopropyl)adenosine, 0.066) = CHA (N6-(cyclohexyl)adenosine, 0.082) greater than NECA (N5-(ethyl-carboxamido)adenosine 0.44) greater than ADO (adenosine, 4.1). ATP was nearly equipotent with ADO. Maximum inhibition was 70%-80% and similar for all agonists.(ABSTRACT TRUNCATED AT 250 WORDS)
Immunolocalisation of P2Y receptors in the rat eye.
Pintor J, Sanchez-Nogueiro J, Irazu M, Mediero A, Pelaez T, Peral A Purinergic Signal. 2008; 1(1):83-90.
PMID: 18404404 PMC: 2096566. DOI: 10.1007/s11302-004-5072-5.
Bernhard M, Takeda K, Keller C, Haslebacher M, Lambrou G, Trendelenburg A Naunyn Schmiedebergs Arch Pharmacol. 2004; 370(4):305-13.
PMID: 15375642 DOI: 10.1007/s00210-004-0972-z.
Hardy T, Brock J Br J Pharmacol. 1999; 126(8):1761-8.
PMID: 10372818 PMC: 1565967. DOI: 10.1038/sj.bjp.0702514.
Goncalves J, Queiroz G Br J Pharmacol. 1996; 117(1):156-60.
PMID: 8825357 PMC: 1909367. DOI: 10.1111/j.1476-5381.1996.tb15168.x.
Kurz K, von Kugelgen I, Starke K Br J Pharmacol. 1993; 110(4):1465-72.
PMID: 8306088 PMC: 2175891. DOI: 10.1111/j.1476-5381.1993.tb13986.x.